Abstract
The topoisomerase enzymes are essential for DNA metabolism, where they act to adjust the number of supercoils in DNA, a key requirement in the cellular processes of transcription and replication. Their enzymatic mechanism creates transient nicks (type I) or breaks (type II) in the double stranded DNA polymer, allowing DNA to be converted between topological isomers. Humans possess both types of topoisomerase enzymes, however the two types utilize very different enzymatic mechanisms. Both type I and type II topoisomerases have been identified as clinically important targets for cancer chemotherapy and their inhibitors are central components in many therapeutic regimes. Over the course of the last 30 years inhibitors with extensive structural diversity have been developed through a combination of drug screening and rational design programs. Simultaneously much emphasis has been placed upon establishing the mechanisms of action of both classes of topoisomerase enzyme. Crucial structural insights have come from the crystal structure of topoisomerase I, while modelling comparisons are beginning to map out a possible framework for topoisomerase II action. This review discusses these recent advances in the fields of enzyme mechanism and inhibitor design. We also address the development of drug resistance and dose-limiting side effects as well as cover alternative methods in drug delivery.
Keywords: topoisomerase, inhibitor, camptothecin, topotecan, anthracycline, anthracenedione, drug design
Medicinal Chemistry
Title: Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy
Volume: 1 Issue: 4
Author(s): Gregory I. Giles and Ram P. Sharma
Affiliation:
Keywords: topoisomerase, inhibitor, camptothecin, topotecan, anthracycline, anthracenedione, drug design
Abstract: The topoisomerase enzymes are essential for DNA metabolism, where they act to adjust the number of supercoils in DNA, a key requirement in the cellular processes of transcription and replication. Their enzymatic mechanism creates transient nicks (type I) or breaks (type II) in the double stranded DNA polymer, allowing DNA to be converted between topological isomers. Humans possess both types of topoisomerase enzymes, however the two types utilize very different enzymatic mechanisms. Both type I and type II topoisomerases have been identified as clinically important targets for cancer chemotherapy and their inhibitors are central components in many therapeutic regimes. Over the course of the last 30 years inhibitors with extensive structural diversity have been developed through a combination of drug screening and rational design programs. Simultaneously much emphasis has been placed upon establishing the mechanisms of action of both classes of topoisomerase enzyme. Crucial structural insights have come from the crystal structure of topoisomerase I, while modelling comparisons are beginning to map out a possible framework for topoisomerase II action. This review discusses these recent advances in the fields of enzyme mechanism and inhibitor design. We also address the development of drug resistance and dose-limiting side effects as well as cover alternative methods in drug delivery.
Export Options
About this article
Cite this article as:
Giles I. Gregory and Sharma P. Ram, Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy, Medicinal Chemistry 2005; 1 (4) . https://dx.doi.org/10.2174/1573406054368738
DOI https://dx.doi.org/10.2174/1573406054368738 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Hypocholesterolemia
Current Vascular Pharmacology Acute Physical Stress Increases Serum Levels of Specific microRNAs
MicroRNA Current Use of Cardiac Biomarkers in Various Heart Conditions
Endocrine, Metabolic & Immune Disorders - Drug Targets Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line
Recent Patents on Anti-Cancer Drug Discovery Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Current Pharmaceutical Design Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Abietane Diterpenes as Potential Candidates for the Management of Type 2 Diabetes
Current Pharmaceutical Design